The findings, presented by Dr. Eugenie Bassères of the University of Houston, reveal that Enterococcus species often create a protective microenvironment that hampers the efficacy of standard antibiotics. While vancomycin and fidaxomicin struggled against these conditions, ibezapolstat demonstrated a 5.51-log reduction in C. difficile, significantly outperforming vancomycin. Furthermore, the drug effectively suppressed toxin B expression and eradicated vancomycin-resistant Enterococcus (VRE) overgrowth, a frequent complication in recurrent infections.

Kevin Garey, professor at the University of Houston College of Pharmacy, noted that the data reinforces ibezapolstat’s ability to target harmful bacteria while preserving the broader gut microbiome. Acurx Pharmaceuticals is now preparing to move the candidate into international Phase 3 clinical trials, aiming to address the high recurrence rates associated with current CDI treatments. The company recently held a Type C meeting with the FDA to align on the registration program, with potential pathways for an NDA submission depending on the robustness of upcoming clinical data.